Veterinary Psychopharmacology. (Record no. 7520)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11114nam a22004813i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC5630287 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724113510.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2019 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781119226246 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781119226222 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC5630287 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL5630287 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1082215765 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | SF756.84 .C769 2019 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Crowell-Davis, Sharon L. |
| 245 10 - TITLE STATEMENT | |
| Title | Veterinary Psychopharmacology. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 2nd ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Newark : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2019. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2019. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (333 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- Title Page -- Copyright Page -- Contents -- Contributors -- Preface -- Acknowledgments -- Part I Principles of Veterinary Psychopharmacology -- Chapter 1 General Principles of Psychopharmacology -- Drug Action -- Dose Dependence of Drug Interaction with Receptors -- Structural Features of the Central Nervous System (CNS) and Neurotransmission -- Biogenic Amine Neurotransmitters and Affective Disorders -- References -- Chapter 2 Amino Acid Neurotransmitters: Glutamate, GABA, and the Pharmacology of Benzodiazepines -- Introduction -- Glutamatergic Synapses -- Pharmacology of Ketamine and Tiletamine -- GABAergic Synapses -- References -- Chapter 3 Biogenic Amine Neurotransmitters: Serotonin -- Introduction -- The Biogenic Amines -- Serotonin -- References -- Chapter 4 Biogenic Amine Transmitters: Acetylcholine, Norepinephrine, and Dopamine -- Acetylcholine -- Norepinephrine -- Dopamine -- References -- Chapter 5 Neuropeptides: Opioids and Oxytocin -- Introduction -- Endogenous Opioid Peptides -- Oxytocin -- References -- Part II Practice of Veterinary Psychopharmacology -- Chapter 6 Introduction to Clinical Psychopharmacology for Veterinary Medicine -- Introduction -- Prescribing in the United States: The Animal Medicinal Drug Use Clarification Act (AMDUCA 1994) -- Cost -- Drug Selection -- Medicating the Patient -- Competition Animals -- Taking the Behavioral History -- The Behavioral Exam -- Duration of Treatment -- Limitations -- References -- Chapter 7 Benzodiazepines -- Action -- Overview of Indications -- Contraindications, Side Effects, and Adverse Events -- Overdose -- Clinical Guidelines -- Specific Medications -- I. Alprazolam -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Doses in Nonhuman Animals -- Discontinuation -- Other Information -- Effects Documented in Nonhuman Animals. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | II. Chlordiazepoxide HC1 -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Doses in Nonhuman Animals -- Discontinuation -- Other Information -- Effects Documented in Nonhuman Animals -- III. Clonazepam -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Drug Interactions -- Overdose -- Doses in Nonhuman Animals -- Discontinuation -- Other Information -- Effects Documented in Nonhuman Animals -- IV. Clorazepate Dipotassium -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Dependence -- Overdose -- Doses in Nonhuman Animals -- Effects Documented in Nonhuman Animals -- V. Diazepam -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Doses in Nonhuman Animals -- Discontinuation -- Other -- Effects Documented in Nonhuman Animals -- VI. Flurazepam Hydrochloride -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Doses in Nonhuman Animals -- Effects Documented in Nonhuman Animals -- VII. Lorazepam -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Doses in Nonhuman Animals -- Discontinuation -- Effects Documented in Nonhuman Animals -- VIII. Oxazepam -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Doses in Nonhuman Animals -- Discontinuation -- Other Information -- Effects Documented in Nonhuman Animals -- IX. Triazolam -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Doses in Nonhuman Animals -- Effects Documented in Nonhuman Animals -- Important Information for Owners of Pets Being Placed on Any Benzodiazepine -- References -- Chapter 8 Selective Serotonin Reuptake Inhibitors -- Action -- Overview of Indications. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Contraindications, Side Effects, and Adverse Events -- Adverse Drug Interactions -- Overdose -- Clinical Guidelines -- Specific Medications -- I. Citalopram Hydrobromide -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Other Information -- Effects Documented in Nonhuman Animals -- II. Fluoxetine Hydrochloride -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Doses in Nonhuman Animals -- Discontinuation of Fluoxetine -- Other Information -- Effects Documented in Nonhuman Animals -- III. Fluvoxamine -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Other Information -- Effects Documented in Nonhuman Animals -- IV. Paroxetine Hydrochloride -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Discontinuation of Paroxetine -- Other Information -- Effects Documented in Nonhuman Animals -- V. Sertraline Hydrochloride -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Other Information -- Effects Documented in Nonhuman Animals -- VI. Escitalopram Oxalate -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Other Information -- Effects Documented in Nonhuman Animals -- Important Information for Owners of Pets Being Placed on Any SSRI -- References -- Chapter 9 Miscellaneous Serotonergic Agents -- Introduction -- Azapirones -- Action -- Overview of Indications -- Contraindications, Side Effects, and Adverse Events -- Adverse Drug Interactions -- Overdose -- Clinical Guidelines -- Specific Medications -- I. Buspirone -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Other Information -- Effects Documented in Nonhuman Animals. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Serotonin Antagonist/Reuptake Inhibitors (SARIs) -- Action -- Overview of Indications -- Contraindications, Side Effects, and Adverse Events -- Adverse Drug Interactions -- Overdose -- Clinical Guidelines -- Specific Medications -- I. Trazodone Hydrochloride -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Other Information -- Effects Documented in Nonhuman Animals -- Note -- References -- Chapter 10 Anticonvulsants and Mood Stabilizers -- Action -- Overview of Indications -- Clinical Guidelines -- Specific Medications -- I. Carbamazepine -- Clinical Pharmacology -- Side Effects -- Effects in Non‐human Animals -- II. Gabapentin -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Doses in Nonhuman Animals -- Other Information -- Effects Documented in Non‐human Animals -- Cattle -- III. Pregabalin -- Clinical Pharmacology -- Uses in Humans -- Side Effects -- Effects Documented in Nonhuman Animals -- References -- Chapter 11 Sympatholytic Agents -- Action -- Overview of Indications -- Contraindications, Side Effects, and Adverse Events -- Overdose -- Clinical Guidelines (Table 11.1) -- Specific Medications -- I. Clonidine -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Other Information -- Effects Documented in Nonhuman Animals -- II. Detomidine -- Clinical Pharmacology -- Use in Humans -- Contraindications -- Side Effects -- Other Information -- Effects Documented in Nonhuman Animals -- III. Dexmedetomidine -- Clinical Pharmacology -- Use in Humans -- Contraindications -- Side Effects -- Effects Documented in Nonhuman Animals -- IV. Propranolol -- Clinical Pharmacology -- Use in Humans -- Contraindications -- Side Effects -- Effects Documented in Nonhuman Animals -- References. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 12 N-Methyl-D-Aspartate (NMDA) Receptor Antagonists -- Action -- Overview of Indications -- Contraindications/Side Effects, and Adverse Events -- Clinical Guidelines -- Specific Medications -- I. Dextromethorphan -- Clinical Pharmacology -- Contraindications and Side Effects -- Other Information -- Effects Documented in Nonhuman Animals -- Horses -- II. Amantadine -- Clinical Pharmacology -- Use in Humans -- Contraindications -- Side Effects -- Overdose -- Effects Documented in Nonhuman Animals -- III. Memantine -- Clinical Pharmacology -- Use in Humans -- Side Effects -- Other Information -- Effects Documented in Nonhuman Animals -- IV. Huperzine A -- Clinical Pharmacology -- Use in Humans -- Overdose and Side Effects -- Effects Documented in Nonhuman Animals -- References -- Chapter 13 Monoamine Oxidase Inhibitors -- Action -- Overview of Indications -- Specific Medications -- I. Selegiline Hydrochloride -- Clinical Pharmacology -- Uses in Humans -- Contraindications -- Side Effects -- Overdose -- Discontinuation -- Other Information -- Effects Documented in Nonhuman Animals -- References -- Chapter 14 Antipsychotics -- Introduction -- Action -- Overview of Indications -- General Pharmacokinetics -- Contraindications, Side Effects, and Adverse Events -- Overdose -- Clinical Guidelines -- Specific Medications -- I. Acepromazine Maleate -- Clinical Pharmacology -- Indications -- Contraindications -- Side Effects -- Adverse Drug Interactions -- Overdose -- Doses in Nonhuman Animals -- Effects Documented in Nonhuman Animals -- II. Azaperone -- Clinical Pharmacology -- Indications -- Doses in Nonhuman Animals -- III. Chlorpromazine -- Clinical Pharmacology -- Uses in Humans -- Indications in Veterinary Medicine -- Contraindications -- Side Effects -- Effects Documented in Nonhuman Animals -- IV. Clozapine -- Clinical Pharmacology. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Uses in Humans. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Veterinary psychopharmacology. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Murray, Thomas F. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | de Souza Dantas, Leticia Mattos. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Crowell-Davis, Sharon L. |
| Title | Veterinary Psychopharmacology |
| Place, publisher, and date of publication | Newark : John Wiley & Sons, Incorporated,c2019 |
| International Standard Book Number | 9781119226222 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5630287">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5630287</a> |
| Public note | Click to View |
No items available.